Ketamine for Methamphetamine Use Disorder
Key facts
- Who runs it
- University of Texas Southwestern Medical Center
- Where
- Albuquerque, Dallas, Greenville, New York, and San Leandro, United StatesSee the 5 sites
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 120 people enrolled
- Started
- 11 Sept 2024
- Ended
- 15 Oct 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ketamine Hydrochloride
- Midazolam Hydrochloride
- Record updated
- 27 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Study participants must:
- Be 18 to 65 years old
- Be able to sufficiently understand, speak, and read English
- Be interested in reducing or stopping methamphetamine use
- Meet criteria for methamphetamine use disorder
- Use acceptable methods of contraception during participation in the study
Who cannot take part
- Have been in a research study of pharmacological or behavioral treatment for addiction within 6 months prior to written informed consent
- Have upcoming surgery planned or scheduled
- Study participants must not:
- Be currently in jail, prison, or inpatient overnight facility as required by court of law
- Be currently pregnant, breastfeeding, or planning on conception, if biologically female; Additional inclusion and exclusion criteria will be assessed by the study investigators at the screening visit
Where in United States
- Interdisciplinary Substance Use and Brain Injury FacilityAlbuquerque, United States
- UT Southwestern Medical CenterDallas, United States
- Prisma HealthGreenville, United States
- Addiction Institute of Mount SinaiNew York, United States
- Alameda Health SystemSan Leandro, United States
About the trial
What the trial wants to find out
This study aims to determine whether treatment response with IV ketamine is superior to treatment response with IV midazolam in adults with moderate to severe MUD.
Read full original descriptionShow less
The study design is a 12-week randomized, double-blind, controlled trial comparing intravenous (IV) ketamine against IV midazolam, delivered over six weeks in 120 adults with moderate to severe methamphetamine use disorder (MUD).
The 2 groups in the trial
- KetamineTreatment being tested
Participants will receive IV ketamine (0.50mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV ketamine will be administered 8 times over 6 weeks.
Treatment: Ketamine Hydrochloride
- MidazolamExisting treatment, for comparison
Participants will receive IV midazolam (0.02mg/kg) dissolved in 0.9% sodium chloride in a total volume of 100mL and administered with an infusion pump at a constant rate over 40 minutes. IV midazolam will be administered 8 times over 6 weeks.
Treatment: Midazolam Hydrochloride
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- NIDA CTN-0132 Randomized, Double-Blind, Active Placebo-Controlled Trial of Ketamine for Methamphetamine Use Disorder (KMD)
- Record updated
- 27 October 2026